• Explore /
  • Poster
  • / The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: An update from MD Anderson Cancer Center.

The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: An update from MD Anderson Cancer Center.

Abstract Poster

Authors

null

Marie-Andree Forget

The University of Texas MD Anderson Cancer Center, Houston, TX

Marie-Andree Forget, Cara L. Haymaker, Kenneth R. Hess, Jason Roszik, Scott Eric Woodman, Orenthial J. Fulbright, Arely Wahl, Esteban Flores, Shawne T. Thorsen, Rene J. Tavera, Renjith Ramachandran, Rodabe Navroze Amaria, Patrick Hwu, Chantale Bernatchez

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells

Sub Track

Adoptive T-cell therapy: Modified and Unmodified Cells

Clinical Trial Registration Number

NCT00338377

Citation

J Clin Oncol 35, 2017 (suppl 7S; abstract 138)

DOI

10.1200/JCO.2017.35.7_suppl.138

Abstract #

138

Poster Bd #

B9

Abstract Disclosures

Similar Posters

Poster

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Final report of a pilot trial combining ipilimumab and adoptive cell therapy.

Final report of a pilot trial combining ipilimumab and adoptive cell therapy.

First Author: John Mullinax

First Author: Rongsu Qi

First Author: Amod Sarnaik

First Author: Amir A. Jazaeri